Advances in antibiotic therapy in the critically ill

被引:0
作者
Jean-Louis Vincent
Matteo Bassetti
Bruno François
George Karam
Jean Chastre
Antoni Torres
Jason A. Roberts
Fabio S. Taccone
Jordi Rello
Thierry Calandra
Daniel De Backer
Tobias Welte
Massimo Antonelli
机构
[1] Université libre de Bruxelles,Department of Intensive Care, Erasme Hospital
[2] Santa Maria Misericordia University Hospital,Infectious Diseases Division
[3] CHU de Dupuytren,Service de Réanimation Polyvalente
[4] Louisiana State University School of Medicine,Infectious Disease Section
[5] Groupe Hospitalier Pitié-Salpêtrière,Réanimation Médicale
[6] Hospital Clinic of Barcelona,Department of Pulmonary Medicine
[7] IDIBAPS-Ciberes,Burns, Trauma and Critical Care Research Centre
[8] The University of Queensland,Department of Intensive care, CIBERES
[9] Royal Brisbane and Women’s Hospital,Infectious Diseases Service
[10] Vall d’Hebron University Hospital,Department of Intensive Care, CHIREC Hospital
[11] Universitat Autonoma de Barcelona,Department of Respiratory Medicine
[12] Centre Hospitalier Universitaire Vaudois,Department of Anesthesiology and Intensive Care Medicine
[13] University of Lausanne,undefined
[14] Université Libre de Bruxelles,undefined
[15] Medizinische Hochschule,undefined
[16] Catholic University of Rome,undefined
[17] A. Gemelli University Hospital,undefined
来源
Critical Care | / 20卷
关键词
Intensive Care Unit Patient; Linezolid; Colistin; Drug Clearance; Ceftaroline;
D O I
暂无
中图分类号
学科分类号
摘要
Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains. In this review, we briefly discuss the importance of early infection diagnosis, before considering in more detail some of the key issues related to antibiotic management in these patients, including controversies surrounding use of combination or monotherapy, duration of therapy, and de-escalation. Antibiotic pharmacodynamics and pharmacokinetics, notably volumes of distribution and clearance, can be altered by critical illness and can influence dosing regimens. Dosing decisions in different subgroups of patients, e.g., the obese, are also covered. We also briefly consider ventilator-associated pneumonia and the role of inhaled antibiotics. Finally, we mention antibiotics that are currently being developed and show promise for the future.
引用
收藏
相关论文
共 583 条
[1]  
Ferrer R(2014)Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program Crit Care Med. 42 1749-1755
[2]  
Martin-Loeches I(2010)Sepsis biomarkers: a review Crit Care. 14 R15-1080
[3]  
Phillips G(2010)An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia Clin Infect Dis 51 1074-1254
[4]  
Osborn TM(2013)Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs Arch Pathol Lab Med. 137 1247-3541
[5]  
Townsend S(2013)Enhanced diagnostic yields of bacteremia and candidemia in blood specimens by PCR-electrospray ionization mass spectrometry J Clin Microbiol. 51 3535-2291
[6]  
Dellinger RP(2015)Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections Crit Care Med. 43 2283-614
[7]  
Pierrakos C(2015)Sepsis: a roadmap for future research Lancet Infect Dis. 15 581-228
[8]  
Vincent JL(2013)Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 Intensive Care Med. 39 165-5322
[9]  
Bauer KA(2010)Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii Antimicrob Agents Chemother. 54 5316-1051
[10]  
West JE(2011)In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii J Antimicrob Chemother. 66 1047-329